- Unyango
- Ubungqina
- I-Neuroblastoma
- Ithumba Eliqinileyo
- Ubungqina
- Ii-TILS
- Unyango lweeSeli zeNK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-NonHodgkin Lymphoma (NHL)
- I-Multiple Myeloma（MM）
- Ukusasaza i-B-cell Lymphom enkulu
- I-B-lymphocytic Leukemia
- I-Myeloma
I-CAR-T ye-Acute B-cell Lymphoblastic Leukemia (B-ALL)
Isishwankathelo
I-B-ALL (Acute B-cell Lymphoblastic Leukemia) luhlobo olubi lwe-leukemia, oluchaphazela kakhulu abantwana kunye nabantu abadala abancinci. Nangona kuhambele phambili kwi-chemotherapy yendabuko, izigulane ezininzi zifumana ukuphinda zibuyele okanye ukunganyangeki kunyango. Unyango lwe-CAR-T (Chimeric Antigen Receptor T-cell) luyindlela entsha yonyango oluye lwabonisa impumelelo ephawulekayo ekunyangeni i-B-ALL ephinde yabuyela okanye enganyangekiyo, nto leyo enika ithemba kwizigulane ebezinazo iindlela zonyango ezimbalwa ngaphambili.
Yintoni i-CAR-T Therapy?
Unyango lwe-CAR-T lunyango oluphucukileyo nolwenzelwe wena olubandakanya ukuguqula ii-T-cells zesigulana ukuze ziqaphele kwaye zihlasele iiseli zomhlaza. Kwi-B-ALL, iiseli ze-CAR-T zenzelwe ukujolisa i-antigen ye-CD19, iproteni efumaneka rhoqo kumphezulu weeseli ze-B-cell leukemia. Nje ukuba zibuyiselwe emzimbeni wesigulana, ezi T-cells zenzelwe ukufuna nokutshabalalisa iiseli ze-leukemia, nto leyo enokubangela ukuba ziphinde zifumane uxolelo oluhlala ixesha elide.
Iingenelo eziphambili ze-CAR-T Therapy kwi-B-ALL
- Ukusebenza OkuphezuluUnyango lwe-CAR-T lubonakalise impumelelo emangalisayo ekunyangeni i-B-ALL ebuyela umva okanye enganyangekiyo, nto leyo enika izinga eliphezulu lokuxolelwa kwizigulana ezingakhange zisabele kunyango lwendabuko.
- Isenzo Esijoliswe Kuso: Ngokugxila kwi-antigen ye-CD19, unyango lwe-CAR-T lujolise kwaye lutshabalalise iiseli ze-B-ALL ngokukodwa, lunciphisa umonakalo kwizicubu ezisempilweni.
- Unyango oluKhethekileyo: Ekubeni iiseli ze-CAR-T zithathwe kwinkqubo yomzimba yesigulana, unyango lwenzelwe umntu ngamnye, lunyusa ukusebenza kwalo kwaye lunciphisa umngcipheko wokwaliwa.
- Uxolelo Oluhlala LuhleliKwiimeko ezininzi, unyango lwe-CAR-T luye lwakhokelela ekuphumleni okuhlala ixesha elide, lunika izigulane ithuba lokuphila ixesha elide kunye nokubuyela umva okuncinci.
Inkqubo Yonyango
- Ukuqokelelwa kwee-T-cellsInyathelo lokuqala libandakanya ukuqokelela ii-T-cells egazini lesigulana ngenkqubo ebizwa ngokuba yi-leukapheresis.
- Iiseli ze-T zobunjineli: Ii-T-cells eziqokelelweyo ziguqulwa ngokwemfuza kwilebhu ukuze ziveze i-chimeric antigen receptor (CAR) ethile kwi-CD19, nto leyo ephucula amandla azo okujolisa kwiiseli ze-B-ALL.
- Ukufakwa kwee-CAR-T CellsEmva kwexesha elifutshane lokukhula kweeseli, iiseli ze-CAR-T ezakhiweyo zibuyiselwa emzimbeni wesigulana ngokufakwa kwe-intravenous (IV).
- Ukubeka iliso kunye nokuBuyisaEmva kokufakwa, izigulane zijongwa ngokusondeleyo ukuze zibone iziphumo ebezingalindelekanga ezifana ne-cytokine release syndrome (CRS) kunye ne-neurotoxicity. Ezi mpendulo zihlala zilawuleka, kwaye uninzi lwezigulane luyaphila ngokungenelela okufanelekileyo.
Kutheni Ukhetha Unyango lwe-BIOOCUS's CAR-T kwi-B-ALL?
- Ubuchwepheshe obuphezulu: I-BIOOCUS isebenzisa iteknoloji yanamhlanje ukuqinisekisa ukuveliswa kweeseli ze-CAR-T ezilungileyo kunye neziphumo zezigulane.
- Iqela leengcali zonyangoIqela lethu leengcali kwi-hematology kunye ne-immunotherapy lizinikele ekuboneleleni ngononophelo lomntu ngamnye kunye nokuphucula impumelelo yonyango ngalunye.
- Amava Amazwe Ngamazwe: Sinikezela ngonyango lwe-CAR-T kwizigulana ezivela kwihlabathi liphela, kunye nerekhodi yonyango oluphumeleleyo kunye nonyango oluhlala ixesha elide kwizigulana ze-B-ALL.
- Ukhathalelo OlupheleleyoUkususela kwingxoxo yokuqala ukuya ekubekweni esweni okulandelayo, i-BIOOCUS ibonelela ngononophelo olupheleleyo, iqinisekisa ukuba izigulana zifumana unyango olungcono kakhulu kwinqanaba ngalinye.
Ubungqina bezonyango kunye namanqanaba empumelelo
Uvavanyo lwakutshanje lweklinikhi kunye nedatha yehlabathi yokwenyani ibonise ukuba unyango lwe-CAR-T lwe-B-ALL lubonelela ngeziphumo ezibalaseleyo, ngakumbi kwizigulana eziphinde zabuyela kwisifo okanye ezingavumiyo unyango lwendabuko. Olu nyango luye lwabonisa amazinga aphezulu okuxolelwa, apho izigulana ezininzi zifikelela ekuxolelweni ngokupheleleyo kwaye zigcina ubomi obude.
Apha kwi-BIOOCUS, siphumelele ukunyanga izigulane ezininzi nge-B-ALL sisebenzisa unyango lwe-CAR-T, kwaye iziphumo zibe ntle kakhulu. Ukuze uqonde ngakumbi amabali empumelelo kunye neziphumo zobomi bokwenyani, nceda uphonononge ezi zifundo zilandelayo zezigulane:
- Ibali lesigulana: I-B-ALL enobungozi obukhulu, ukufakelwa kweBone Marrow kwiinyanga ezili-9—Emva kweminyaka emibini, isiqalo esisempilweni
- Ukusuka Ekungaphumeleli Kokufakelwa Kweentambo Zokuqala Ukuya Ekubuyeleni Ngokupheleleyo: Uhambo Lwesigulana Ngokufakelwa Kweentambo Eziphambili ZikaLu Daopei
- Ulwazi lweMveliso ye-Acute Lymphoblastic Leukemia (B-ALL) kunye neZifundo zeTyala
Ezi meko zibonisa amandla okuguqula unyango lwe-CAR-T kwizigulane ze-B-ALL, zibonisa kungekuphela nje ukusebenza kakuhle konyango kodwa kunye namandla alo okunika izigulane ithuba lesibini ebomini.
Iinkcukacha zeKlinikhi
Iimpawu zeCD19+20CAR-T:Izigulane ezine-B-cell non-Hodgkin's lymphoma
| Izinga le-CR lenyanga enye | Izinga le-PR lenyanga enye | Inyanga enye okanye izinga le-OR | I-CRS≥3 | I-CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55（80/82） | 12.19% (10/82) | 0 |
Iimpawu ze-CD19+22CAR-T:Unyango lwe-CD19 ephinde yabuyela kwi-CD19 kwaye izigulane ezine-B-lymphocytic leukemia ezinesifo esingapheliyo
| Izinga le-CR lenyanga enye | Izinga le-PR lenyanga enye | Inyanga enye okanye izinga le-OR | I-CRS≥3 | I-CRES≥3 |
| 92.1% (35/38) | 7.9%（3/38） | 100% （38/38） | 15.79% (6/38) | 0 |
Iimpawu ze-BCMACAR-T:Unyango lwe-myeloma ephindaphindayo nengasasebenziyo
| Izinga le-CR lenyanga enye | Izinga le-PR lenyanga enye | Inyanga enye okanye izinga le-OR | I-CRS≥3 | I-CRES≥3 |
| 72.41% (21/29) | 27.59%（8/29） | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.